Unknown

Dataset Information

0

Highly synergistic drug combination prevents vaginal HIV infection in humanized mice.


ABSTRACT: The HIV-1 epidemic remains an urgent global health concern. Young women are disproportionately at risk of acquiring the virus. A range of highly effective, female-controlled, discrete vaginal products therefore is needed to help curb the epidemic. Oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are effective in HIV-1 pre-exposure prophylaxis (PrEP) and form a promising basis for a vaginal product. Here, we evaluate TDF and FTC in combination with the broadly neutralizing antibody VRC01-N using a highly reproducible humanized mouse model. The agents were vaginally dosed individually and in combination, and the efficacy of HIV-1 prevention was analyzed using the established, rigorous median-effect model. Surprisingly, the triple combination showed a high degree of synergism, unprecedented for in vivo HIV-1 PrEP, leading to a possible fivefold dose reduction for some of the agents. Vaginal administration of the TDF-FTC-VRC01-N combination holds significant promise for HIV-1 PrEP.

SUBMITTER: Baum MM 

PROVIDER: S-EPMC7400648 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10030891 | biostudies-literature
| S-EPMC8780078 | biostudies-literature
| S-EPMC5182099 | biostudies-literature
| S-EPMC5589224 | biostudies-literature
| S-EPMC4471720 | biostudies-other
| S-EPMC3809838 | biostudies-literature
| S-EPMC8563409 | biostudies-literature
| S-EPMC5983313 | biostudies-literature
| S-EPMC7226910 | biostudies-literature
| S-EPMC3785119 | biostudies-literature